CEL-SCI Corp
$ 6.29
5.54%
04 Dec - close price
- Market Cap 53,144,000 USD
- Current Price $ 6.29
- High / Low $ 6.30 / 5.80
- Stock P/E N/A
- Book Value 1.32
- EPS -9.13
- Next Earning Report 2026-01-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.70 %
- ROE -3.28 %
- 52 Week High 32.70
- 52 Week Low 1.98
About
CEL-SCI Corporation (CVM) is a pioneering biotechnology firm based in Vienna, Virginia, specializing in immunotherapy solutions for cancer and infectious diseases. The company's flagship product candidate, Multikine, is designed to leverage the immune system to effectively target and eliminate tumors, positioning CEL-SCI at the forefront of cancer treatment innovation. With a strong pipeline and a focus on addressing significant unmet medical needs, CEL-SCI is poised to make impactful strides in the biopharmaceutical landscape, appealing to institutional investors seeking opportunities in advancing healthcare solutions.
Analyst Target Price
$42.50
Quarterly Earnings
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-08-12 | 2025-05-13 | 2025-01-13 | 2024-12-31 | 2024-08-14 | 2024-05-15 | 2024-02-14 | 2023-12-21 | 2023-08-10 | 2023-05-12 | 2023-02-14 | 2022-12-27 |
| Reported EPS | -1.36 | -2.3323 | -2.7 | -2.7003 | -0.14 | -0.14 | -0.14 | -0.16 | -0.19 | -0.19 | -0.18 | -0.21 |
| Estimated EPS | None | None | -3.3 | -0.1 | -0.13 | -0.14 | -0.14 | -0.16 | -0.16 | -0.17 | -0.21 | -0.2 |
| Surprise | 0 | 0 | 0.6 | -2.6003 | -0.01 | 0 | 0 | 0 | -0.03 | -0.02 | 0.03 | -0.01 |
| Surprise Percentage | None% | None% | 18.1818% | -2600.3% | -7.6923% | 0% | 0% | 0% | -18.75% | -11.7647% | 14.2857% | -5% |
Next Quarterly Earnings
| Sep 2025 | |
|---|---|
| Reported Date | 2026-01-12 |
| Fiscal Date Ending | 2025-09-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CVM
2025-10-15 09:00:56
Retail investor interest in Cel-Sci Corporation is increasing as the company awaits a decision from the Saudi Food and Drug Authority (SFDA) regarding Breakthrough Medicine Designation for its cancer immunotherapy, Multikine. The SFDA's 60-day review period is ending soon, and approval would grant accelerated patient access and reimbursement for Multikine in Saudi Arabia. This follows a Memorandum of Understanding with a Saudi pharmaceutical company and has attracted interest from Saudi investment funds for expansion in the MENA region.
2025-10-10 08:00:00
CEL-SCI Corporation announced that CEO Geert Kersten will present at the LD Micro "Main Event" investor conference on October 21, 2025, at 9:30 a.m. PST. He will deliver a 20-minute corporate presentation outlining the strategic roadmap for the continued development of Multikine and will be available for one-on-one investor meetings. The conference will take place at the Hotel Del Coronado in San Diego from October 19-21, 2025.
2025-08-27 22:54:00
CEL-SCI Corp. announced the pricing of a public offering of approximately 1.11 million shares of its common stock at $9.00 per share, aiming to raise about $10 million in gross proceeds. The offering is expected to close on August 29, 2025, with net proceeds allocated to the continued development of Multikine, general corporate purposes, and working capital. CEL-SCI Corp. is a clinical stage cancer immunotherapy company.
2025-08-13 09:15:00
CEL-SCI Corporation's cancer immunotherapy, Multikine, is seeking Breakthrough Medicine Designation in Saudi Arabia, which could lead to immediate patient access and reimbursement within approximately 60 days. This follows an MOU with a leading Saudi pharma company for commercialization, with a final partnership agreement expected in Q3 2025. Multikine significantly increased the 5-year survival rate for head and neck cancer patients in its Phase 3 study, and several Saudi funds have expressed investment interest.
2025-07-11 13:15:00
CEL-SCI Corporation announced an agreement with a leading Saudi Arabian pharmaceutical company for the regulatory and commercial activities of Multikine in the Kingdom. The partnership aims to file a Breakthrough Medicine Designation application with the SFDA, which could lead to patient access and reimbursement within approximately 60 days. This collaboration aligns with Saudi Arabia's Vision 2030 and has garnered interest from Saudi investment funds.
2025-05-23 00:00:00
CEL-SCI Corporation announced the closing of its underwritten public offering of 2,000,000 shares of common stock at $2.50 per share, generating gross proceeds of $5,000,000. The company also granted underwriters a 45-day option to purchase up to an additional 190,000 shares. Proceeds will fund the continued development of Multikine, general corporate purposes, and working capital.
